{
    "abstract": "Introduction: Respiratory syncytial virus (RSV)is a leading cause of acute lower respiratory tract infections in infants. An investigational vaccine using an engineered recombinant RSV fusion glycoprotein in its post-fusion conformation (RSV F subunit vaccine)has been developed to protect young infants via maternal immunization. This first-in-human, phase I, observer-blind study (NCT02298179)evaluated the safety and immunogenicity of different dosages and formulations of RSV F subunit vaccine in healthy non-pregnant women and men aged 18\u201345 years. Methods: Participants were enrolled (1:1:1)in a stepwise dosage-escalation manner into three cohorts to receive RSV F subunit vaccine containing 45 \u00b5g, 90 \u00b5g and 135 \u03bcg of RSV F glycoprotein. Within each cohort, participants were randomized (1:1:1:1)to receive two doses of RSV F subunit vaccine with (aluminum hydroxide or MF59)or without adjuvant, or placebo, \u226528 days apart. Safety (until day 365 post-dose 2), anti-RSV neutralizing antibodies (NAbs)and serum total binding antibodies to RSV F protein (until day 181 post-dose 1)were evaluated. Results: All formulations were well-tolerated. No vaccine-related serious adverse events were reported. All participants were seropositive for anti-RSV NAbs at baseline, with geometric mean titers (GMTs)ranging from 184 (95% confidence interval [CI]: 127\u2013266)to 380 (95% CI: 272\u2013531). At 28 days post-dose 1, anti-RSV NAb GMTs in vaccine recipients ranged from 893 (95% CI: 702\u20131,136)to 1,602 (95% CI: 1,243\u20132,064). No booster effect was observed, but immune responses were maintained above pre-vaccination levels for six months post-dose 1. Ratios of RSV F total binding antibodies fold changes to NAb fold changes ranged from 2.79 to 4.12 at 28 days post-dose 1. The impact of the adjuvant was limited. Conclusions: A single dose of each formulation of RSV subunit F vaccine was well-tolerated and enhanced preexisting NAb titers through six months of follow-up.",
    "author_highlights": [
        {
            "endOffset": 17000,
            "sentence": "A RSV F subunit vaccine was developed to protect infants via maternal immunization.",
            "startOffset": 16917
        },
        {
            "endOffset": 17085,
            "sentence": "Different formulations of this vaccine in men and non-pregnant women were evaluated.",
            "startOffset": 17001
        },
        {
            "endOffset": 17152,
            "sentence": "All formulations of the RSV subunit F vaccine were well-tolerated.",
            "startOffset": 17086
        },
        {
            "endOffset": 17232,
            "sentence": "A single dose of this vaccine boosted preexisting neutralizing antibody titers.",
            "startOffset": 17153
        },
        {
            "endOffset": 17308,
            "sentence": "All formulations also induced non-neutralizing antibodies to RSV F protein.",
            "startOffset": 17233
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Eric A.F.",
                    "initial": "E.A.F.",
                    "last": "Simoes"
                }
            ],
            "doi": "10.1016/S0140-6736(99)80040-3",
            "firstpage": "847",
            "issn": "01406736",
            "lastpage": "852",
            "pmid": "10485741",
            "pub_year": 1999,
            "title": "Respiratory syncytial virus infection",
            "volume": "354"
        },
        "b0010": {
            "authors": [
                {
                    "first": "C. B.",
                    "initial": "C.B.",
                    "last": "Hall"
                }
            ],
            "doi": "10.1056/NEJM200106213442507",
            "firstpage": "1917",
            "issn": "00284793",
            "lastpage": "1928",
            "pmid": "11419430",
            "pub_year": 2001,
            "title": "Respiratory syncytial virus and parainfluenza virus",
            "volume": "344"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Caroline Breese",
                    "initial": "C.B.",
                    "last": "Hall"
                },
                {
                    "first": "Geoffrey A.",
                    "initial": "G.A.",
                    "last": "Weinberg"
                },
                {
                    "first": "Marika K.",
                    "initial": "M.K.",
                    "last": "Iwane"
                },
                {
                    "first": "Aaron K.",
                    "initial": "A.K.",
                    "last": "Blumkin"
                },
                {
                    "first": "Kathryn M.",
                    "initial": "K.M.",
                    "last": "Edwards"
                },
                {
                    "first": "Mary A.",
                    "initial": "M.A.",
                    "last": "Staat"
                },
                {
                    "first": "Peggy",
                    "initial": "P.",
                    "last": "Auinger"
                },
                {
                    "first": "Marie R.",
                    "initial": "M.R.",
                    "last": "Griffin"
                },
                {
                    "first": "Katherine A.",
                    "initial": "K.A.",
                    "last": "Poehling"
                },
                {
                    "first": "Dean",
                    "initial": "D.",
                    "last": "Erdman"
                },
                {
                    "first": "Carlos G.",
                    "initial": "C.G.",
                    "last": "Grijalva"
                },
                {
                    "first": "Yuwei",
                    "initial": "Y.",
                    "last": "Zhu"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Szilagyi"
                }
            ],
            "doi": "10.1056/NEJMoa0804877",
            "firstpage": "588",
            "issn": "00284793",
            "lastpage": "598",
            "pmid": "19196675",
            "pub_year": 2009,
            "title": "The Burden of respiratory syncytial virus infection in young children",
            "volume": "360"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Marika K.",
                    "initial": "M.K.",
                    "last": "Iwane"
                },
                {
                    "first": "Kathryn M.",
                    "initial": "K.M.",
                    "last": "Edwards"
                },
                {
                    "first": "Peter G.",
                    "initial": "P.G.",
                    "last": "Szilagyi"
                },
                {
                    "first": "Frances J.",
                    "initial": "F.J.",
                    "last": "Walker"
                },
                {
                    "first": "Marie R.",
                    "initial": "M.R.",
                    "last": "Griffin"
                },
                {
                    "first": "Geoffrey A.",
                    "initial": "G.A.",
                    "last": "Weinberg"
                },
                {
                    "first": "Charmaine",
                    "initial": "C.",
                    "last": "Coulen"
                },
                {
                    "first": "Katherine A.",
                    "initial": "K.A.",
                    "last": "Poehling"
                },
                {
                    "first": "Laura P.",
                    "initial": "L.P.",
                    "last": "Shone"
                },
                {
                    "first": "Sharon",
                    "initial": "S.",
                    "last": "Balter"
                },
                {
                    "first": "Caroline B.",
                    "initial": "C.B.",
                    "last": "Hall"
                },
                {
                    "first": "Dean D.",
                    "initial": "D.D.",
                    "last": "Erdman"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "Wooten"
                },
                {
                    "first": "Benjamin",
                    "initial": "B.",
                    "last": "Schwartz"
                }
            ],
            "doi": "10.1542/peds.113.6.1758",
            "firstpage": "1758",
            "issn": "00314005",
            "lastpage": "1764",
            "pmid": "15173503",
            "pub_year": 2004,
            "title": "Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children",
            "volume": "113"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Ting",
                    "initial": "T.",
                    "last": "Shi"
                },
                {
                    "first": "David A.",
                    "initial": "D.A.",
                    "last": "McAllister"
                },
                {
                    "first": "Katherine L.",
                    "initial": "K.L.",
                    "last": "O'Brien"
                },
                {
                    "first": "Eric A.F.",
                    "initial": "E.A.F.",
                    "last": "Simoes"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Bradford D.",
                    "initial": "B.D.",
                    "last": "Gessner"
                },
                {
                    "first": "Fernando P.",
                    "initial": "F.P.",
                    "last": "Polack"
                },
                {
                    "first": "Evelyn",
                    "initial": "E.",
                    "last": "Balsells"
                },
                {
                    "first": "Sozinho",
                    "initial": "S.",
                    "last": "Acacio"
                },
                {
                    "first": "Claudia",
                    "initial": "C.",
                    "last": "Aguayo"
                },
                {
                    "first": "Issifou",
                    "initial": "I.",
                    "last": "Alassani"
                },
                {
                    "first": "Asad",
                    "initial": "A.",
                    "last": "Ali"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Antonio"
                },
                {
                    "first": "Shally",
                    "initial": "S.",
                    "last": "Awasthi"
                },
                {
                    "first": "Juliet O.",
                    "initial": "J.O.",
                    "last": "Awori"
                },
                {
                    "first": "Eduardo",
                    "initial": "E.",
                    "last": "Azziz-Baumgartner"
                },
                {
                    "first": "Henry C.",
                    "initial": "H.C.",
                    "last": "Baggett"
                },
                {
                    "first": "Vicky L.",
                    "initial": "V.L.",
                    "last": "Baillie"
                },
                {
                    "first": "Angel",
                    "initial": "A.",
                    "last": "Balmaseda"
                },
                {
                    "first": "Alfredo",
                    "initial": "A.",
                    "last": "Barahona"
                },
                {
                    "first": "Sudha",
                    "initial": "S.",
                    "last": "Basnet"
                },
                {
                    "first": "Quique",
                    "initial": "Q.",
                    "last": "Bassat"
                },
                {
                    "first": "Wilma",
                    "initial": "W.",
                    "last": "Basualdo"
                },
                {
                    "first": "Godfrey",
                    "initial": "G.",
                    "last": "Bigogo"
                },
                {
                    "first": "Louis",
                    "initial": "L.",
                    "last": "Bont"
                },
                {
                    "first": "Robert F.",
                    "initial": "R.F.",
                    "last": "Breiman"
                },
                {
                    "first": "W. Abdullah",
                    "initial": "W.A.",
                    "last": "Brooks"
                },
                {
                    "first": "Shobha",
                    "initial": "S.",
                    "last": "Broor"
                },
                {
                    "first": "Nigel",
                    "initial": "N.",
                    "last": "Bruce"
                },
                {
                    "first": "Dana",
                    "initial": "D.",
                    "last": "Bruden"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Buchy"
                },
                {
                    "first": "Stuart",
                    "initial": "S.",
                    "last": "Campbell"
                },
                {
                    "first": "Phyllis",
                    "initial": "P.",
                    "last": "Carosone-Link"
                },
                {
                    "first": "Mandeep",
                    "initial": "M.",
                    "last": "Chadha"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Chipeta"
                },
                {
                    "first": "Monidarin",
                    "initial": "M.",
                    "last": "Chou"
                },
                {
                    "first": "Wilfrido",
                    "initial": "W.",
                    "last": "Clara"
                },
                {
                    "first": "Cheryl",
                    "initial": "C.",
                    "last": "Cohen"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "de Cuellar"
                },
                {
                    "first": "Duc Anh",
                    "initial": "D.A.",
                    "last": "Dang"
                },
                {
                    "first": "Budragchaagiin",
                    "initial": "B.",
                    "last": "Dash-yandag"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Deloria-Knoll"
                },
                {
                    "first": "Mukesh",
                    "initial": "M.",
                    "last": "Dherani"
                },
                {
                    "first": "Tekchheng",
                    "initial": "T.",
                    "last": "Eap"
                },
                {
                    "first": "Bernard E.",
                    "initial": "B.E.",
                    "last": "Ebruke"
                },
                {
                    "first": "Marcela",
                    "initial": "M.",
                    "last": "Echavarria"
                },
                {
                    "first": "Carla Cec\u00edlia",
                    "initial": "C.C.",
                    "last": "de Freitas L\u00e1zaro Emediato"
                },
                {
                    "first": "Rodrigo A.",
                    "initial": "R.A.",
                    "last": "Fasce"
                },
                {
                    "first": "Daniel R.",
                    "initial": "D.R.",
                    "last": "Feikin"
                },
                {
                    "first": "Luzhao",
                    "initial": "L.",
                    "last": "Feng"
                },
                {
                    "first": "Angela",
                    "initial": "A.",
                    "last": "Gentile"
                },
                {
                    "first": "Aubree",
                    "initial": "A.",
                    "last": "Gordon"
                },
                {
                    "first": "Doli",
                    "initial": "D.",
                    "last": "Goswami"
                },
                {
                    "first": "Sophie",
                    "initial": "S.",
                    "last": "Goyet"
                },
                {
                    "first": "Michelle",
                    "initial": "M.",
                    "last": "Groome"
                },
                {
                    "first": "Natasha",
                    "initial": "N.",
                    "last": "Halasa"
                },
                {
                    "first": "Siddhivinayak",
                    "initial": "S.",
                    "last": "Hirve"
                },
                {
                    "first": "Nusrat",
                    "initial": "N.",
                    "last": "Homaira"
                },
                {
                    "first": "Stephen R.C.",
                    "initial": "S.R.C.",
                    "last": "Howie"
                },
                {
                    "first": "Jorge",
                    "initial": "J.",
                    "last": "Jara"
                },
                {
                    "first": "Imane",
                    "initial": "I.",
                    "last": "Jroundi"
                },
                {
                    "first": "Cissy B.",
                    "initial": "C.B.",
                    "last": "Kartasasmita"
                },
                {
                    "first": "Najwa",
                    "initial": "N.",
                    "last": "Khuri-Bulos"
                },
                {
                    "first": "Karen L.",
                    "initial": "K.L.",
                    "last": "Kotloff"
                },
                {
                    "first": "Anand",
                    "initial": "A.",
                    "last": "Krishnan"
                },
                {
                    "first": "Romina",
                    "initial": "R.",
                    "last": "Libster"
                },
                {
                    "first": "Olga",
                    "initial": "O.",
                    "last": "Lopez"
                },
                {
                    "first": "Marilla G.",
                    "initial": "M.G.",
                    "last": "Lucero"
                },
                {
                    "first": "Florencia",
                    "initial": "F.",
                    "last": "Lucion"
                },
                {
                    "first": "Socorro P.",
                    "initial": "S.P.",
                    "last": "Lupisan"
                },
                {
                    "first": "Debora N.",
                    "initial": "D.N.",
                    "last": "Marcone"
                },
                {
                    "first": "John P.",
                    "initial": "J.P.",
                    "last": "McCracken"
                },
                {
                    "first": "Mario",
                    "initial": "M.",
                    "last": "Mejia"
                },
                {
                    "first": "Jennifer C.",
                    "initial": "J.C.",
                    "last": "Moisi"
                },
                {
                    "first": "Joel M.",
                    "initial": "J.M.",
                    "last": "Montgomery"
                },
                {
                    "first": "David P.",
                    "initial": "D.P.",
                    "last": "Moore"
                },
                {
                    "first": "Cinta",
                    "initial": "C.",
                    "last": "Moraleda"
                },
                {
                    "first": "Jocelyn",
                    "initial": "J.",
                    "last": "Moyes"
                },
                {
                    "first": "Patrick",
                    "initial": "P.",
                    "last": "Munywoki"
                },
                {
                    "first": "Kuswandewi",
                    "initial": "K.",
                    "last": "Mutyara"
                },
                {
                    "first": "Mark P.",
                    "initial": "M.P.",
                    "last": "Nicol"
                },
                {
                    "first": "D. James",
                    "initial": "D.J.",
                    "last": "Nokes"
                },
                {
                    "first": "Pagbajabyn",
                    "initial": "P.",
                    "last": "Nymadawa"
                },
                {
                    "first": "Maria Tereza",
                    "initial": "M.T.",
                    "last": "da Costa Oliveira"
                },
                {
                    "first": "Histoshi",
                    "initial": "H.",
                    "last": "Oshitani"
                },
                {
                    "first": "Nitin",
                    "initial": "N.",
                    "last": "Pandey"
                },
                {
                    "first": "Gl\u00e1ucia",
                    "initial": "G.",
                    "last": "Paranhos-Baccal\u00e0"
                },
                {
                    "first": "Lia N.",
                    "initial": "L.N.",
                    "last": "Phillips"
                },
                {
                    "first": "Valentina Sanchez",
                    "initial": "V.S.",
                    "last": "Picot"
                },
                {
                    "first": "Mustafizur",
                    "initial": "M.",
                    "last": "Rahman"
                },
                {
                    "first": "Mala",
                    "initial": "M.",
                    "last": "Rakoto-Andrianarivelo"
                },
                {
                    "first": "Zeba A.",
                    "initial": "Z.A.",
                    "last": "Rasmussen"
                },
                {
                    "first": "Barbara A.",
                    "initial": "B.A.",
                    "last": "Rath"
                },
                {
                    "first": "Annick",
                    "initial": "A.",
                    "last": "Robinson"
                },
                {
                    "first": "Candice",
                    "initial": "C.",
                    "last": "Romero"
                },
                {
                    "first": "Graciela",
                    "initial": "G.",
                    "last": "Russomando"
                },
                {
                    "first": "Vahid",
                    "initial": "V.",
                    "last": "Salimi"
                },
                {
                    "first": "Pongpun",
                    "initial": "P.",
                    "last": "Sawatwong"
                },
                {
                    "first": "Nienke",
                    "initial": "N.",
                    "last": "Scheltema"
                },
                {
                    "first": "Brunhilde",
                    "initial": "B.",
                    "last": "Schweiger"
                },
                {
                    "first": "J. Anthony G.",
                    "initial": "J.A.G.",
                    "last": "Scott"
                },
                {
                    "first": "Phil",
                    "initial": "P.",
                    "last": "Seidenberg"
                },
                {
                    "first": "Kunling",
                    "initial": "K.",
                    "last": "Shen"
                },
                {
                    "first": "Rosalyn",
                    "initial": "R.",
                    "last": "Singleton"
                },
                {
                    "first": "Viviana",
                    "initial": "V.",
                    "last": "Sotomayor"
                },
                {
                    "first": "Tor A.",
                    "initial": "T.A.",
                    "last": "Strand"
                },
                {
                    "first": "Agustinus",
                    "initial": "A.",
                    "last": "Sutanto"
                },
                {
                    "first": "Mariam",
                    "initial": "M.",
                    "last": "Sylla"
                },
                {
                    "first": "Milagritos D.",
                    "initial": "M.D.",
                    "last": "Tapia"
                },
                {
                    "first": "Somsak",
                    "initial": "S.",
                    "last": "Thamthitiwat"
                },
                {
                    "first": "Elizabeth D.",
                    "initial": "E.D.",
                    "last": "Thomas"
                },
                {
                    "first": "Rafal",
                    "initial": "R.",
                    "last": "Tokarz"
                },
                {
                    "first": "Claudia",
                    "initial": "C.",
                    "last": "Turner"
                },
                {
                    "first": "Marietjie",
                    "initial": "M.",
                    "last": "Venter"
                },
                {
                    "first": "Sunthareeya",
                    "initial": "S.",
                    "last": "Waicharoen"
                },
                {
                    "first": "Jianwei",
                    "initial": "J.",
                    "last": "Wang"
                },
                {
                    "first": "Wanitda",
                    "initial": "W.",
                    "last": "Watthanaworawit"
                },
                {
                    "first": "Lay Myint",
                    "initial": "L.M.",
                    "last": "Yoshida"
                },
                {
                    "first": "Hongjie",
                    "initial": "H.",
                    "last": "Yu"
                },
                {
                    "first": "Heather J.",
                    "initial": "H.J.",
                    "last": "Zar"
                },
                {
                    "first": "Harry",
                    "initial": "H.",
                    "last": "Campbell"
                },
                {
                    "first": "Harish",
                    "initial": "H.",
                    "last": "Nair"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1016/S0140-6736(17)30938-8",
            "firstpage": "946",
            "issn": "01406736",
            "lastpage": "958",
            "pmid": "28689664",
            "pub_year": 2017,
            "title": "Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study",
            "volume": "390"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Alexandra B.",
                    "initial": "A.B.",
                    "last": "Hogan"
                },
                {
                    "first": "Kathryn",
                    "initial": "K.",
                    "last": "Glass"
                },
                {
                    "first": "Hannah C.",
                    "initial": "H.C.",
                    "last": "Moore"
                },
                {
                    "first": "Robert S.",
                    "initial": "R.S.",
                    "last": "Anderssen"
                }
            ],
            "doi": "10.1016/j.tpb.2016.04.003",
            "firstpage": "78",
            "issn": "00405809",
            "lastpage": "85",
            "pmid": "27155294",
            "pub_year": 2016,
            "title": "Exploring the dynamics of respiratory syncytial virus (RSV) transmission in children",
            "volume": "110"
        },
        "b0035": {
            "authors": [
                {
                    "first": "W. Paul",
                    "initial": "W.P.",
                    "last": "Glezen"
                },
                {
                    "first": "Larry H.",
                    "initial": "L.H.",
                    "last": "Taber"
                },
                {
                    "first": "Arthur L.",
                    "initial": "A.L.",
                    "last": "Frank"
                },
                {
                    "first": "Julius A.",
                    "initial": "J.A.",
                    "last": "Kasel"
                }
            ],
            "doi": "10.1001/archpedi.1986.02140200053026",
            "firstpage": "543",
            "issn": "0002922X",
            "lastpage": "546",
            "pmid": "3706232",
            "pub_year": 1986,
            "title": "Risk of Primary Infection and Reinfection With Respiratory Syncytial Virus",
            "volume": "140"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Harish",
                    "initial": "H.",
                    "last": "Nair"
                },
                {
                    "first": "D. James",
                    "initial": "D.J.",
                    "last": "Nokes"
                },
                {
                    "first": "Bradford D.",
                    "initial": "B.D.",
                    "last": "Gessner"
                },
                {
                    "first": "Mukesh",
                    "initial": "M.",
                    "last": "Dherani"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Rosalyn J.",
                    "initial": "R.J.",
                    "last": "Singleton"
                },
                {
                    "first": "Katherine L.",
                    "initial": "K.L.",
                    "last": "O'Brien"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Roca"
                },
                {
                    "first": "Peter F.",
                    "initial": "P.F.",
                    "last": "Wright"
                },
                {
                    "first": "Nigel",
                    "initial": "N.",
                    "last": "Bruce"
                },
                {
                    "first": "Aruna",
                    "initial": "A.",
                    "last": "Chandran"
                },
                {
                    "first": "Evropi",
                    "initial": "E.",
                    "last": "Theodoratou"
                },
                {
                    "first": "Agustinus",
                    "initial": "A.",
                    "last": "Sutanto"
                },
                {
                    "first": "Endang R.",
                    "initial": "E.R.",
                    "last": "Sedyaningsih"
                },
                {
                    "first": "Mwanajuma",
                    "initial": "M.",
                    "last": "Ngama"
                },
                {
                    "first": "Patrick K.",
                    "initial": "P.K.",
                    "last": "Munywoki"
                },
                {
                    "first": "Cissy",
                    "initial": "C.",
                    "last": "Kartasasmita"
                },
                {
                    "first": "Eric AF",
                    "initial": "E.A.",
                    "last": "Sim\u00f5es"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Rudan"
                },
                {
                    "first": "Martin W.",
                    "initial": "M.W.",
                    "last": "Weber"
                },
                {
                    "first": "Harry",
                    "initial": "H.",
                    "last": "Campbell"
                }
            ],
            "doi": "10.1016/S0140-6736(10)60206-1",
            "firstpage": "1545",
            "issn": "01406736",
            "lastpage": "1555",
            "pmid": "20399493",
            "pub_year": 2010,
            "title": "Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis",
            "volume": "375"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Patricia A.",
                    "initial": "P.A.",
                    "last": "Jorquera"
                },
                {
                    "first": "Ralph A.",
                    "initial": "R.A.",
                    "last": "Tripp"
                }
            ],
            "doi": "10.1080/17476348.2017.1338567",
            "firstpage": "609",
            "issn": "17476348",
            "lastpage": "615",
            "pmid": "28574729",
            "pub_year": 2017,
            "title": "Respiratory syncytial virus: prospects for new and emerging therapeutics",
            "volume": "11"
        },
        "b0050": {
            "authors": [
                {
                    "first": "William A.",
                    "initial": "W.A.",
                    "last": "Prescott"
                },
                {
                    "first": "Fred",
                    "initial": "F.",
                    "last": "Doloresco"
                },
                {
                    "first": "Jack",
                    "initial": "J.",
                    "last": "Brown"
                },
                {
                    "first": "Joseph A.",
                    "initial": "J.A.",
                    "last": "Paladino"
                }
            ],
            "doi": "10.2165/11531860-000000000-00000",
            "firstpage": "279",
            "issn": "11707690",
            "lastpage": "293",
            "pub_year": 2010,
            "title": "Cost effectiveness of respiratory syncytial virus prophylaxis: A critical and systematic review",
            "volume": "28"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Kayvon",
                    "initial": "K.",
                    "last": "Modjarrad"
                },
                {
                    "first": "Birgitte",
                    "initial": "B.",
                    "last": "Giersing"
                },
                {
                    "first": "David C.",
                    "initial": "D.C.",
                    "last": "Kaslow"
                },
                {
                    "first": "Peter G.",
                    "initial": "P.G.",
                    "last": "Smith"
                },
                {
                    "first": "Vasee S.",
                    "initial": "V.S.",
                    "last": "Moorthy"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.05.093",
            "firstpage": "190",
            "issn": "0264410X",
            "lastpage": "197",
            "pmid": "26100926",
            "pub_year": 2016,
            "title": "WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015",
            "volume": "34"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Barney S.",
                    "initial": "B.S.",
                    "last": "Graham"
                }
            ],
            "doi": "10.1111/j.1600-065X.2010.00972.x",
            "firstpage": "149",
            "issn": "01052896",
            "lastpage": "166",
            "pmid": "21198670",
            "pub_year": 2011,
            "title": "Biological challenges and technological opportunities for respiratory syncytial virus vaccine development",
            "volume": "239"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Judith",
                    "initial": "J.",
                    "last": "Falloon"
                },
                {
                    "first": "Jing",
                    "initial": "J.",
                    "last": "Yu"
                },
                {
                    "first": "Mark T.",
                    "initial": "M.T.",
                    "last": "Esser"
                },
                {
                    "first": "Tonya",
                    "initial": "T.",
                    "last": "Villafana"
                },
                {
                    "first": "Li",
                    "initial": "L.",
                    "last": "Yu"
                },
                {
                    "first": "Filip",
                    "initial": "F.",
                    "last": "Dubovsky"
                },
                {
                    "first": "Therese",
                    "initial": "T.",
                    "last": "Takas"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Ann R.",
                    "initial": "A.R.",
                    "last": "Falsey"
                }
            ],
            "doi": "10.1093/infdis/jix503",
            "firstpage": "1362",
            "issn": "00221899",
            "lastpage": "1370",
            "pmid": "29029260",
            "pub_year": 2017,
            "title": "An adjuvanted, postfusion F protein-based vaccine did not prevent respiratory syncytial virus illness in older adults",
            "volume": "216"
        },
        "b0070": null,
        "b0075": {
            "authors": [
                {
                    "first": "W. Paul",
                    "initial": "W.P.",
                    "last": "Glezen"
                },
                {
                    "first": "Abel",
                    "initial": "A.",
                    "last": "Paredes"
                },
                {
                    "first": "James E.",
                    "initial": "J.E.",
                    "last": "Allison"
                },
                {
                    "first": "Larry H.",
                    "initial": "L.H.",
                    "last": "Taber"
                },
                {
                    "first": "Arthur L.",
                    "initial": "A.L.",
                    "last": "Frank"
                }
            ],
            "doi": "10.1016/S0022-3476(81)80829-3",
            "firstpage": "708",
            "issn": "00223476",
            "lastpage": "715",
            "pub_year": 1981,
            "title": "Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level",
            "volume": "98"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Natalie I.",
                    "initial": "N.I.",
                    "last": "Mazur"
                },
                {
                    "first": "Nicole M.",
                    "initial": "N.M.",
                    "last": "Horsley"
                },
                {
                    "first": "Janet A.",
                    "initial": "J.A.",
                    "last": "Englund"
                },
                {
                    "first": "Maaike",
                    "initial": "M.",
                    "last": "Nederend"
                },
                {
                    "first": "Amalia",
                    "initial": "A.",
                    "last": "Magaret"
                },
                {
                    "first": "Azad",
                    "initial": "A.",
                    "last": "Kumar"
                },
                {
                    "first": "Shamir R.",
                    "initial": "S.R.",
                    "last": "Jacobino"
                },
                {
                    "first": "Cornelis A.M.",
                    "initial": "C.A.M.",
                    "last": "De Haan"
                },
                {
                    "first": "Subarna K.",
                    "initial": "S.K.",
                    "last": "Khatry"
                },
                {
                    "first": "Steven C.",
                    "initial": "S.C.",
                    "last": "Leclerq"
                },
                {
                    "first": "Mark C.",
                    "initial": "M.C.",
                    "last": "Steinhoff"
                },
                {
                    "first": "James M.",
                    "initial": "J.M.",
                    "last": "Tielsch"
                },
                {
                    "first": "Joanne",
                    "initial": "J.",
                    "last": "Katz"
                },
                {
                    "first": "Barney S.",
                    "initial": "B.S.",
                    "last": "Graham"
                },
                {
                    "first": "Louis J.",
                    "initial": "L.J.",
                    "last": "Bont"
                },
                {
                    "first": "Jeanette H.W.",
                    "initial": "J.H.W.",
                    "last": "Leusen"
                },
                {
                    "first": "Helen Y.",
                    "initial": "H.Y.",
                    "last": "Chu"
                }
            ],
            "doi": "10.1093/infdis/jiy477",
            "firstpage": "59",
            "issn": "00221899",
            "lastpage": "67",
            "pmid": "30107412",
            "pub_year": 2018,
            "title": "Breast milk prefusion F immunoglobulin g as a correlate of protection against respiratory syncytial virus acute respiratory illness",
            "volume": "219"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Rachel",
                    "initial": "R.",
                    "last": "Ochola"
                },
                {
                    "first": "Charles",
                    "initial": "C.",
                    "last": "Sande"
                },
                {
                    "first": "Gregory",
                    "initial": "G.",
                    "last": "Fegan"
                },
                {
                    "first": "Paul D.",
                    "initial": "P.D.",
                    "last": "Scott"
                },
                {
                    "first": "Graham F.",
                    "initial": "G.F.",
                    "last": "Medley"
                },
                {
                    "first": "Patricia A.",
                    "initial": "P.A.",
                    "last": "Cane"
                },
                {
                    "first": "D. James",
                    "initial": "D.J.",
                    "last": "Nokes"
                }
            ],
            "doi": "10.1371/journal.pone.0008088",
            "issn": "19326203",
            "pmid": "19956576",
            "pub_year": 2009,
            "title": "The level and duration of RSV-specific maternal IgG in infants in kilifi Kenya",
            "volume": "4"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Marie M.",
                    "initial": "M.M.",
                    "last": "Ogilvie"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Santhire Vathenen"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Radford"
                },
                {
                    "first": "Janet",
                    "initial": "J.",
                    "last": "Codd"
                },
                {
                    "first": "Sheila",
                    "initial": "S.",
                    "last": "Key"
                }
            ],
            "doi": "10.1002/jmv.1890070403",
            "firstpage": "263",
            "issn": "01466615",
            "lastpage": "271",
            "pmid": "7038043",
            "pub_year": 1981,
            "title": "Maternal antibody and respiratory syncytial virus infection in infancy",
            "volume": "7"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Pedro A.",
                    "initial": "P.A.",
                    "last": "Piedra"
                },
                {
                    "first": "Alan M.",
                    "initial": "A.M.",
                    "last": "Jewell"
                },
                {
                    "first": "Stanley G.",
                    "initial": "S.G.",
                    "last": "Cron"
                },
                {
                    "first": "Robert L.",
                    "initial": "R.L.",
                    "last": "Atmar"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Paul Glezen"
                }
            ],
            "doi": "10.1016/S0264-410X(03)00355-4",
            "firstpage": "3479",
            "issn": "0264410X",
            "lastpage": "3482",
            "pmid": "12850364",
            "pub_year": 2003,
            "title": "Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: Establishment of minimum protective threshold levels of serum neutralizing antibodies",
            "volume": "21"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Gayatri",
                    "initial": "G.",
                    "last": "Amirthalingam"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Campbell"
                },
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Ribeiro"
                },
                {
                    "first": "Norman K.",
                    "initial": "N.K.",
                    "last": "Fry"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Ramsay"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                },
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Andrews"
                }
            ],
            "doi": "10.1093/cid/ciw559",
            "firstpage": "S236",
            "issn": "10584838",
            "lastpage": "S243",
            "pmid": "27838678",
            "pub_year": 2016,
            "title": "Sustained effectiveness of the maternal pertussis immunization program in England 3 years following introduction",
            "volume": "63"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Vittorio",
                    "initial": "V.",
                    "last": "Demicheli"
                },
                {
                    "first": "Antonella",
                    "initial": "A.",
                    "last": "Barale"
                },
                {
                    "first": "Alessandro",
                    "initial": "A.",
                    "last": "Rivetti"
                }
            ],
            "doi": "10.1002/14651858.CD002959.pub4",
            "issn": "1469493X",
            "pmid": "26144877",
            "pub_year": 2015,
            "title": "Vaccines for women for preventing neonatal tetanus",
            "volume": "2015"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Philipp",
                    "initial": "P.",
                    "last": "Lambach"
                },
                {
                    "first": "Joachim",
                    "initial": "J.",
                    "last": "Hombach"
                },
                {
                    "first": "Justin R.",
                    "initial": "J.R.",
                    "last": "Ortiz"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.08.036",
            "firstpage": "6376",
            "issn": "0264410X",
            "lastpage": "6379",
            "pmid": "26319068",
            "pub_year": 2015,
            "title": "A global perspective of maternal influenza immunization",
            "volume": "33"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Pablo A.",
                    "initial": "P.A.",
                    "last": "Gonz\u00e1lez"
                },
                {
                    "first": "Susan M.",
                    "initial": "S.M.",
                    "last": "Bueno"
                },
                {
                    "first": "Leandro J.",
                    "initial": "L.J.",
                    "last": "Carre\u00f1o"
                },
                {
                    "first": "Claudia A.",
                    "initial": "C.A.",
                    "last": "Riedel"
                },
                {
                    "first": "Alexis M.",
                    "initial": "A.M.",
                    "last": "Kalergis"
                }
            ],
            "doi": "10.1002/rmv.1704",
            "firstpage": "230",
            "issn": "10529276",
            "lastpage": "244",
            "pmid": "22290692",
            "pub_year": 2012,
            "title": "Respiratory syncytial virus infection and immunity",
            "volume": "22"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Jason S.",
                    "initial": "J.S.",
                    "last": "McLellan"
                },
                {
                    "first": "William C.",
                    "initial": "W.C.",
                    "last": "Ray"
                },
                {
                    "first": "Mark E.",
                    "initial": "M.E.",
                    "last": "Peeples"
                }
            ],
            "doi": "10.1007/978-3-642-38919-1-4",
            "firstpage": "83",
            "issn": "0070217X",
            "lastpage": "104",
            "pmid": "24362685",
            "pub_year": 2013,
            "title": "Structure and function of respiratory syncytial virus surface glycoproteins",
            "volume": "372"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Kurt A.",
                    "initial": "K.A.",
                    "last": "Swanson"
                },
                {
                    "first": "Ethan C.",
                    "initial": "E.C.",
                    "last": "Settembre"
                },
                {
                    "first": "Christine A.",
                    "initial": "C.A.",
                    "last": "Shaw"
                },
                {
                    "first": "Antu K.",
                    "initial": "A.K.",
                    "last": "Dey"
                },
                {
                    "first": "Rino",
                    "initial": "R.",
                    "last": "Rappuoli"
                },
                {
                    "first": "Christian W.",
                    "initial": "C.W.",
                    "last": "Mandl"
                },
                {
                    "first": "Philip R.",
                    "initial": "P.R.",
                    "last": "Dormitzer"
                },
                {
                    "first": "Andrea",
                    "initial": "A.",
                    "last": "Carfi"
                }
            ],
            "doi": "10.1073/pnas.1106536108",
            "firstpage": "9619",
            "issn": "00278424",
            "lastpage": "9624",
            "pmid": "21586636",
            "pub_year": 2011,
            "title": "Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers",
            "volume": "108"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Ji\u0159i",
                    "initial": "J.",
                    "last": "Beran"
                },
                {
                    "first": "Jason D.",
                    "initial": "J.D.",
                    "last": "Lickliter"
                },
                {
                    "first": "Tino F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "Casey",
                    "initial": "C.",
                    "last": "Johnson"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Chu"
                },
                {
                    "first": "Joseph B.",
                    "initial": "J.B.",
                    "last": "Domachowske"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Van Damme"
                },
                {
                    "first": "Kanchanamala",
                    "initial": "K.",
                    "last": "Withanage"
                },
                {
                    "first": "Laurence A.",
                    "initial": "L.A.",
                    "last": "Fissette"
                },
                {
                    "first": "Marie Pierre",
                    "initial": "M.P.",
                    "last": "David"
                },
                {
                    "first": "Koen",
                    "initial": "K.",
                    "last": "Maleux"
                },
                {
                    "first": "Alexander C.",
                    "initial": "A.C.",
                    "last": "Schmidt"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Picciolato"
                },
                {
                    "first": "Ilse",
                    "initial": "I.",
                    "last": "Dieussaert"
                }
            ],
            "doi": "10.1093/infdis/jiy065",
            "firstpage": "1616",
            "issn": "00221899",
            "lastpage": "1625",
            "pmid": "29401325",
            "pub_year": 2018,
            "title": "Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results from 2 Phase 2 Trials",
            "volume": "217"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Michele",
                    "initial": "M.",
                    "last": "Pellegrini"
                },
                {
                    "first": "Uwe",
                    "initial": "U.",
                    "last": "Nicolay"
                },
                {
                    "first": "Kelly",
                    "initial": "K.",
                    "last": "Lindert"
                },
                {
                    "first": "Nicola",
                    "initial": "N.",
                    "last": "Groth"
                },
                {
                    "first": "Giovanni",
                    "initial": "G.",
                    "last": "Della Cioppa"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.08.101",
            "firstpage": "6959",
            "issn": "0264410X",
            "lastpage": "6965",
            "pmid": "19751689",
            "pub_year": 2009,
            "title": "MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database",
            "volume": "27"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Joanne M.",
                    "initial": "J.M.",
                    "last": "Langley"
                },
                {
                    "first": "Naresh",
                    "initial": "N.",
                    "last": "Aggarwal"
                },
                {
                    "first": "Azhar",
                    "initial": "A.",
                    "last": "Toma"
                },
                {
                    "first": "Scott A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "Shelly A.",
                    "initial": "S.A.",
                    "last": "McNeil"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Fissette"
                },
                {
                    "first": "Walthere",
                    "initial": "W.",
                    "last": "Dew\u00e9"
                },
                {
                    "first": "Maarten",
                    "initial": "M.",
                    "last": "Leyssen"
                },
                {
                    "first": "Jean Fran\u00e7ois",
                    "initial": "J.F.",
                    "last": "Toussaint"
                },
                {
                    "first": "Ilse",
                    "initial": "I.",
                    "last": "Dieussaert"
                }
            ],
            "doi": "10.1093/infdis/jiw453",
            "firstpage": "24",
            "issn": "15376613",
            "lastpage": "33",
            "pmid": "27694633",
            "pub_year": 2017,
            "title": "A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant",
            "volume": "215"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Gregory M.",
                    "initial": "G.M.",
                    "last": "Glenn"
                },
                {
                    "first": "Louis F.",
                    "initial": "L.F.",
                    "last": "Fries"
                },
                {
                    "first": "D. Nigel",
                    "initial": "D.N.",
                    "last": "Thomas"
                },
                {
                    "first": "Gale",
                    "initial": "G.",
                    "last": "Smith"
                },
                {
                    "first": "Eloi",
                    "initial": "E.",
                    "last": "Kpamegan"
                },
                {
                    "first": "Hanxin",
                    "initial": "H.",
                    "last": "Lu"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Flyer"
                },
                {
                    "first": "Dewal",
                    "initial": "D.",
                    "last": "Jani"
                },
                {
                    "first": "Somia P.",
                    "initial": "S.P.",
                    "last": "Hickman"
                },
                {
                    "first": "Pedro A.",
                    "initial": "P.A.",
                    "last": "Piedra"
                }
            ],
            "doi": "10.1093/infdis/jiv406",
            "firstpage": "411",
            "issn": "00221899",
            "lastpage": "422",
            "pmid": "26259809",
            "pub_year": 2016,
            "title": "A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant Fusion (F) nanoparticle vaccine in healthy women of childbearing age",
            "volume": "213"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Thorunn A.",
                    "initial": "T.A.",
                    "last": "Olafsdottir"
                },
                {
                    "first": "Kristjan F.",
                    "initial": "K.F.",
                    "last": "Alexandersson"
                },
                {
                    "first": "Gardar",
                    "initial": "G.",
                    "last": "Sveinbjornsson"
                },
                {
                    "first": "Giulia",
                    "initial": "G.",
                    "last": "Lapini"
                },
                {
                    "first": "Laura",
                    "initial": "L.",
                    "last": "Palladino"
                },
                {
                    "first": "Emanuele",
                    "initial": "E.",
                    "last": "Montomoli"
                },
                {
                    "first": "Giuseppe",
                    "initial": "G.",
                    "last": "Del Giudice"
                },
                {
                    "first": "Daniel F.",
                    "initial": "D.F.",
                    "last": "Gudbjartsson"
                },
                {
                    "first": "Ingileif",
                    "initial": "I.",
                    "last": "Jonsdottir"
                }
            ],
            "doi": "10.3389/fimmu.2017.01872",
            "issn": "16643224",
            "pub_year": 2018,
            "title": "Age and influenza-specific pre-vaccination antibodies strongly affect influenza vaccine responses in the icelandic population whereas disease and medication have small effects",
            "volume": "8"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Yang",
                    "initial": "Y.",
                    "last": "Zhang"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Meyer-Hermann"
                },
                {
                    "first": "Laura A.",
                    "initial": "L.A.",
                    "last": "George"
                },
                {
                    "first": "Marc Thilo",
                    "initial": "M.T.",
                    "last": "Figge"
                },
                {
                    "first": "Mahmood",
                    "initial": "M.",
                    "last": "Khan"
                },
                {
                    "first": "Margaret",
                    "initial": "M.",
                    "last": "Goodall"
                },
                {
                    "first": "Stephen P.",
                    "initial": "S.P.",
                    "last": "Young"
                },
                {
                    "first": "Adam",
                    "initial": "A.",
                    "last": "Reynolds"
                },
                {
                    "first": "Francesco",
                    "initial": "F.",
                    "last": "Falciani"
                },
                {
                    "first": "Ari",
                    "initial": "A.",
                    "last": "Waisman"
                },
                {
                    "first": "Clare A.",
                    "initial": "C.A.",
                    "last": "Notley"
                },
                {
                    "first": "Michael R.",
                    "initial": "M.R.",
                    "last": "Ehrenstein"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Kosco-Vilbois"
                },
                {
                    "first": "Kai Michael",
                    "initial": "K.M.",
                    "last": "Toellner"
                }
            ],
            "doi": "10.1084/jem.20120150",
            "firstpage": "457",
            "issn": "00221007",
            "lastpage": "464",
            "pmid": "23420879",
            "pub_year": 2013,
            "title": "Germinal center B cells govern their own fate via antibody feedback",
            "volume": "210"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Gregory M.",
                    "initial": "G.M.",
                    "last": "Glenn"
                },
                {
                    "first": "Gale",
                    "initial": "G.",
                    "last": "Smith"
                },
                {
                    "first": "Louis",
                    "initial": "L.",
                    "last": "Fries"
                },
                {
                    "first": "Rama",
                    "initial": "R.",
                    "last": "Raghunandan"
                },
                {
                    "first": "Hanxin",
                    "initial": "H.",
                    "last": "Lu"
                },
                {
                    "first": "Bin",
                    "initial": "B.",
                    "last": "Zhou"
                },
                {
                    "first": "D. Nigel",
                    "initial": "D.N.",
                    "last": "Thomas"
                },
                {
                    "first": "Somia P.",
                    "initial": "S.P.",
                    "last": "Hickman"
                },
                {
                    "first": "Eloi",
                    "initial": "E.",
                    "last": "Kpamegan"
                },
                {
                    "first": "Sarathi",
                    "initial": "S.",
                    "last": "Boddapati"
                },
                {
                    "first": "Pedro A.",
                    "initial": "P.A.",
                    "last": "Piedra"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.11.009",
            "firstpage": "524",
            "issn": "0264410X",
            "lastpage": "532",
            "pmid": "23153449",
            "pub_year": 2013,
            "title": "Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine",
            "volume": "31"
        },
        "b0165": {
            "authors": [
                {
                    "first": "Cristina",
                    "initial": "C.",
                    "last": "Capella"
                },
                {
                    "first": "Supranee",
                    "initial": "S.",
                    "last": "Chaiwatpongsakorn"
                },
                {
                    "first": "Erin",
                    "initial": "E.",
                    "last": "Gorrell"
                },
                {
                    "first": "Zachary A.",
                    "initial": "Z.A.",
                    "last": "Risch"
                },
                {
                    "first": "Fang",
                    "initial": "F.",
                    "last": "Ye"
                },
                {
                    "first": "Sara E.",
                    "initial": "S.E.",
                    "last": "Mertz"
                },
                {
                    "first": "Sara M.",
                    "initial": "S.M.",
                    "last": "Johnson"
                },
                {
                    "first": "Melissa",
                    "initial": "M.",
                    "last": "Moore-Clingenpeel"
                },
                {
                    "first": "Octavio",
                    "initial": "O.",
                    "last": "Ramilo"
                },
                {
                    "first": "Asuncion",
                    "initial": "A.",
                    "last": "Mejias"
                },
                {
                    "first": "Mark E.",
                    "initial": "M.E.",
                    "last": "Peeples"
                }
            ],
            "doi": "10.1093/infdis/jix489",
            "firstpage": "1398",
            "issn": "00221899",
            "lastpage": "1406",
            "pmid": "29029312",
            "pub_year": 2017,
            "title": "Prefusion F, postfusion F, G antibodies, and disease severity in infants and young children with acute respiratory syncytial virus infection",
            "volume": "216"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Joan O.",
                    "initial": "J.O.",
                    "last": "Ngwuta"
                },
                {
                    "first": "Man",
                    "initial": "M.",
                    "last": "Chen"
                },
                {
                    "first": "Kayvon",
                    "initial": "K.",
                    "last": "Modjarrad"
                },
                {
                    "first": "M. Gordon",
                    "initial": "M.G.",
                    "last": "Joyce"
                },
                {
                    "first": "Masaru",
                    "initial": "M.",
                    "last": "Kanekiyo"
                },
                {
                    "first": "Azad",
                    "initial": "A.",
                    "last": "Kumar"
                },
                {
                    "first": "Hadi M.",
                    "initial": "H.M.",
                    "last": "Yassine"
                },
                {
                    "first": "Syed M.",
                    "initial": "S.M.",
                    "last": "Moin"
                },
                {
                    "first": "April M.",
                    "initial": "A.M.",
                    "last": "Killikelly"
                },
                {
                    "first": "Gwo Yu",
                    "initial": "G.Y.",
                    "last": "Chuang"
                },
                {
                    "first": "Aliaksandr",
                    "initial": "A.",
                    "last": "Druz"
                },
                {
                    "first": "Ivelin S.",
                    "initial": "I.S.",
                    "last": "Georgiev"
                },
                {
                    "first": "Emily J.",
                    "initial": "E.J.",
                    "last": "Rundlet"
                },
                {
                    "first": "Mallika",
                    "initial": "M.",
                    "last": "Sastry"
                },
                {
                    "first": "Guillaume B.E.",
                    "initial": "G.B.E.",
                    "last": "Stewart-Jones"
                },
                {
                    "first": "Yongping",
                    "initial": "Y.",
                    "last": "Yang"
                },
                {
                    "first": "Baoshan",
                    "initial": "B.",
                    "last": "Zhang"
                },
                {
                    "first": "Martha C.",
                    "initial": "M.C.",
                    "last": "Nason"
                },
                {
                    "first": "Cristina",
                    "initial": "C.",
                    "last": "Capella"
                },
                {
                    "first": "Mark E.",
                    "initial": "M.E.",
                    "last": "Peeples"
                },
                {
                    "first": "Julie E.",
                    "initial": "J.E.",
                    "last": "Ledgerwood"
                },
                {
                    "first": "Jason S.",
                    "initial": "J.S.",
                    "last": "McLellan"
                },
                {
                    "first": "Peter D.",
                    "initial": "P.D.",
                    "last": "Kwong"
                },
                {
                    "first": "Barney S.",
                    "initial": "B.S.",
                    "last": "Graham"
                }
            ],
            "doi": "10.1126/scitranslmed.aac4241",
            "issn": "19466234",
            "pmid": "26468324",
            "pub_year": 2015,
            "title": "Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera",
            "volume": "7"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Ivy",
                    "initial": "I.",
                    "last": "Widjaja"
                },
                {
                    "first": "Oliver",
                    "initial": "O.",
                    "last": "Wicht"
                },
                {
                    "first": "Willem",
                    "initial": "W.",
                    "last": "Luytjes"
                },
                {
                    "first": "Kees",
                    "initial": "K.",
                    "last": "Leenhouts"
                },
                {
                    "first": "Peter J.M.",
                    "initial": "P.J.M.",
                    "last": "Rottier"
                },
                {
                    "first": "Frank J.M.",
                    "initial": "F.J.M.",
                    "last": "van Kuppeveld"
                },
                {
                    "first": "Bert Jan",
                    "initial": "B.J.",
                    "last": "Haijema"
                },
                {
                    "first": "Cornelis A.M.",
                    "initial": "C.A.M.",
                    "last": "de Haan"
                }
            ],
            "doi": "10.1128/JVI.00235-16",
            "firstpage": "5965",
            "issn": "0022538X",
            "lastpage": "5977",
            "pmid": "27099320",
            "pub_year": 2016,
            "title": "Characterization of epitope-specific anti-respiratory syncytial virus (anti-RSV) antibody responses after natural infection and after vaccination with formalin-inactivated RSV",
            "volume": "90"
        },
        "b0180": {
            "authors": [
                {
                    "first": "Emily",
                    "initial": "E.",
                    "last": "Phung"
                },
                {
                    "first": "Lauren A.",
                    "initial": "L.A.",
                    "last": "Chang"
                },
                {
                    "first": "Kaitlyn M.",
                    "initial": "K.M.",
                    "last": "Morabito"
                },
                {
                    "first": "Masaru",
                    "initial": "M.",
                    "last": "Kanekiyo"
                },
                {
                    "first": "Man",
                    "initial": "M.",
                    "last": "Chen"
                },
                {
                    "first": "Deepika",
                    "initial": "D.",
                    "last": "Nair"
                },
                {
                    "first": "Azad",
                    "initial": "A.",
                    "last": "Kumar"
                },
                {
                    "first": "Grace L.",
                    "initial": "G.L.",
                    "last": "Chen"
                },
                {
                    "first": "Julie E.",
                    "initial": "J.E.",
                    "last": "Ledgerwood"
                },
                {
                    "first": "Barney S.",
                    "initial": "B.S.",
                    "last": "Graham"
                },
                {
                    "first": "Tracy J.",
                    "initial": "T.J.",
                    "last": "Ruckwardt"
                }
            ],
            "doi": "10.3390/vaccines7010023",
            "issn": "2076393X",
            "pub_year": 2019,
            "title": "Epitope-specific serological assays for RSV: Conformation matters",
            "volume": "7"
        }
    },
    "body_text": [
        {
            "endOffset": 45006,
            "parents": [],
            "refoffsets": {
                "b0170": {
                    "endOffset": 45005,
                    "startOffset": 45001
                }
            },
            "secId": "s0065",
            "sentence": "However, the efficacy of the site II\u2013specific antibodies palivizumab and motavizumab suggest that, at least in young children, there is a concentration of anti-site II antibodies that can protect against RSV disease [34].",
            "startOffset": 44785,
            "title": "Discussion"
        },
        {
            "endOffset": 22810,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This phase I, observer-blind, randomized, placebo-controlled, dosage-escalation study was conducted at the Ghent University Hospital, Belgium from December 2014 to March 2017.",
            "startOffset": 22635,
            "title": "Study design and participants"
        },
        {
            "endOffset": 35192,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "No fatal SAEs were reported.",
            "startOffset": 35164,
            "title": "Safety"
        },
        {
            "endOffset": 36607,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "NAb GMTs at Day 181 were slightly higher in the RSV F subunit-Al group (NAb GMT: 788; 2.23-fold increase from baseline) and the RSV F-MF59 group (NAb GMT: 764; 2.16-fold increase from baseline) of the 135 \u00b5g cohort than in the other groups.",
            "startOffset": 36367,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 31040,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "For all treatment groups within each cohort, GMTs of the serum anti-RSV NAbs and of the serum total binding antibodies to each of the RSV F, G and N proteins were computed with their associated 95% confidence intervals (CIs) by exponentiation of the corresponding log-transformed means and 95% CIs.",
            "startOffset": 30742,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 36871,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "No increases in anti-RSV NAb GMTs were observed in the participants from the 3 cohorts who received the placebo.",
            "startOffset": 36759,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 40858,
            "parents": [],
            "refoffsets": {
                "b0150": {
                    "endOffset": 40857,
                    "startOffset": 40853
                }
            },
            "secId": "s0065",
            "sentence": "A strong negative effect of pre-vaccination titers on vaccine responses was previously observed following influenza vaccination [30].",
            "startOffset": 40725,
            "title": "Discussion"
        },
        {
            "endOffset": 22892,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Healthy non-pregnant women and men aged 18\u201345 years were enrolled in a 3:1 ratio.",
            "startOffset": 22811,
            "title": "Study design and participants"
        },
        {
            "endOffset": 24800,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki.",
            "startOffset": 24684,
            "title": "Study design and participants"
        },
        {
            "endOffset": 35029,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Among recipients of the 135 \u00b5g dosage, one SAE was reported in the non-adjuvanted RSV F subunit group (head injury) and two SAEs were reported in the RSV F subunit-Al group (anaphylactic shock and depression).",
            "startOffset": 34820,
            "title": "Safety"
        },
        {
            "endOffset": 23151,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "More women were enrolled as the RSV F subunit vaccine is intended for use in pregnant women, but men were also included since this was a first-in-human trial and the vaccine may also be tested in the future in other groups of population, such as the elderly.",
            "startOffset": 22893,
            "title": "Study design and participants"
        },
        {
            "endOffset": 45658,
            "parents": [],
            "secId": "s0070",
            "sentence": "A single dose of the RSV F subunit vaccine induced increases in NAb titers, but no booster effect was observed after the second dose.",
            "startOffset": 45525,
            "title": "Conclusions"
        },
        {
            "endOffset": 27913,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Blood was collected from all participants at Days 1, 29, 57 and 181 for serology assays.",
            "startOffset": 27825,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 34819,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "For recipients of the 90 \u00b5g dosage, one SAE was reported in the non-adjuvanted RSV F subunit group (acute pyelonephritis) and four SAEs were reported in the RSV F subunit-MF59 group (Basedow-Graves disease, pyelonephritis, intervertebral disc degeneration and vaginal hemorrhage).",
            "startOffset": 34539,
            "title": "Safety"
        },
        {
            "endOffset": 29464,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Due to the use of a distinctly labeled bead type per antigen, antibody levels against RSV F, N, Ga and Gb proteins could be quantified in a single sample volume and assay run by a phytoerythrin-labeled detection antibody.",
            "startOffset": 29243,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 22417,
            "parents": [],
            "secId": "s0005",
            "sentence": "By immunizing pregnant women during the third trimester of gestation, the use of the RSV F subunit vaccine aims to increase the level of NAbs that are passively transferred to the infants placentally and to protect them from RSV disease during their first months of life.",
            "startOffset": 22146,
            "title": "Introduction"
        },
        {
            "endOffset": 29943,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The target sample size was to enroll 288 healthy adults to obtain 260 evaluable participants, considered as sufficient to provide a descriptive summary of the safety and immunogenicity of the vaccine.",
            "startOffset": 29743,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 45086,
            "parents": [],
            "secId": "s0065",
            "sentence": "This study was limited by its observer-blinded design and the small sample size.",
            "startOffset": 45006,
            "title": "Discussion"
        },
        {
            "endOffset": 24416,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Participants with a positive urine pregnancy test prior to study vaccinations or lactating women were excluded from the study.",
            "startOffset": 24290,
            "title": "Study design and participants"
        },
        {
            "endOffset": 31765,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "For each timepoint, the percentages of seropositive participants for anti-RSV NAbs, the ratios of the serum total binding antibody titers to the RSV F protein to the NAb titers, and the geometric mean ratios (GMRs) of the RSV F total binding antibody titer fold changes to the NAb titer fold changes were also computed with their 95% CIs.",
            "startOffset": 31427,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 34016,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Unsolicited AEs reported between Day 1 and Day 28 led to withdrawal from the second vaccination for one participant in the non-adjuvanted RSV F subunit group of the 45 \u00b5g cohort (urticaria) and one participant in the RSV F subunit-Al group of the 135 \u00b5g cohort (otitis media); these participants were excluded from the unsolicited safety set post-dose 2, but did not withdraw from the study.",
            "startOffset": 33625,
            "title": "Safety"
        },
        {
            "endOffset": 32519,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Most participants were White/Caucasian (92% to 100%).",
            "startOffset": 32466,
            "title": "Study population"
        },
        {
            "endOffset": 37342,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "All participants had pre-existing antibodies against the RSV F protein, with serum total binding antibody GMTs to the RSV F protein ranging from 671 to 916 across groups at baseline (Table 3).",
            "startOffset": 37150,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 24613,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "To ensure the participants\u2019 safety, each study vaccine recipient becoming pregnant during the study had to be followed-up even if the intended duration of safety follow-up for the study had ended.",
            "startOffset": 24417,
            "title": "Study design and participants"
        },
        {
            "endOffset": 39196,
            "parents": [],
            "secId": "s0065",
            "sentence": "Our study also showed that all formulations induced increases in non-neutralizing serum total binding antibodies, but that no booster effect was observed after the second vaccine dose.",
            "startOffset": 39012,
            "title": "Discussion"
        },
        {
            "endOffset": 40724,
            "parents": [],
            "secId": "s0065",
            "sentence": "This observation can probably be explained by the relatively large proportion of participants with high titers at baseline.",
            "startOffset": 40601,
            "title": "Discussion"
        },
        {
            "endOffset": 27797,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Hematological and biochemical parameters were measured at Days 1, 8, 29, 36 and 57 (Supplement 2).",
            "startOffset": 27699,
            "title": "Safety assessment"
        },
        {
            "endOffset": 45524,
            "parents": [],
            "secId": "s0070",
            "sentence": "In summary, this phase 1 study showed that the three increasing dosages of the RSV F subunit vaccine, with or without aluminum or MF59 adjuvant, had a clinically acceptable safety profile.",
            "startOffset": 45336,
            "title": "Conclusions"
        },
        {
            "endOffset": 28196,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Virus neutralization was performed by incubating a fixed amount of RSV-A (strain A Long, ATCC No. VR-26) with serial dilutions of the test serum.",
            "startOffset": 28051,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 20425,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 20424,
                    "startOffset": 20421
                }
            },
            "secId": "s0005",
            "sentence": "Oxygen therapy or antiviral ribavirin aerosols may be used for the treatment of severe RSV disease [9].",
            "startOffset": 20322,
            "title": "Introduction"
        },
        {
            "endOffset": 31189,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The statistical analyses for GMTs were conducted using an ANCOVA model with dosage and adjuvant as factors and baseline antibody level as covariate.",
            "startOffset": 31041,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 40600,
            "parents": [],
            "secId": "s0065",
            "sentence": "In our study, a low percentage of participants had a post-vaccination 4-fold increase in NAb titers compared with baseline.",
            "startOffset": 40477,
            "title": "Discussion"
        },
        {
            "endOffset": 33624,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Any unsolicited AE was reported by 54\u201371% (no adjuvant RSV F subunit groups), 58\u201363% (RSV F subunit-Al groups), 58\u201367% (RSV F subunit-MF59 groups) and 58\u201371% (placebo) of participants post-dose 1.",
            "startOffset": 33428,
            "title": "Safety"
        },
        {
            "endOffset": 21722,
            "parents": [],
            "refoffsets": {
                "b0100": {
                    "endOffset": 21721,
                    "startOffset": 21714
                },
                "b0105": {
                    "endOffset": 21721,
                    "startOffset": 21714
                },
                "b0110": {
                    "endOffset": 21721,
                    "startOffset": 21714
                }
            },
            "secId": "s0005",
            "sentence": "Such maternal immunization programs have been proven safe and effective for prevention of neonatal tetanus, pertussis and influenza [20\u201322].",
            "startOffset": 21582,
            "title": "Introduction"
        },
        {
            "endOffset": 39011,
            "parents": [],
            "secId": "s0065",
            "sentence": "A single vaccine dose induced increases in NAb titers, which were within the same range for all vaccine formulations.",
            "startOffset": 38894,
            "title": "Discussion"
        },
        {
            "endOffset": 30446,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The safety analysis was performed in the solicited (for solicited local and systemic symptoms) and the unsolicited (for unsolicited AEs, NOCDs and SAEs) safety sets at each timepoint, which included all participants receiving at least one study vaccination and who provided safety data at the relevant timepoint.",
            "startOffset": 30134,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 39690,
            "parents": [],
            "secId": "s0065",
            "sentence": "The first dose of the RSV F subunit vaccine elicited 3.21- to 4.58-fold increases in NAb GMTs.",
            "startOffset": 39596,
            "title": "Discussion"
        },
        {
            "endOffset": 32310,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "A total of 288 healthy female and male adults 18\u201345 years of age were enrolled (Fig. 2).",
            "startOffset": 32222,
            "title": "Study population"
        },
        {
            "endOffset": 41750,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 41749,
                    "startOffset": 41742
                },
                "b0160": {
                    "endOffset": 41749,
                    "startOffset": 41742
                }
            },
            "secId": "s0065",
            "sentence": "A similar poor booster effect has been previously observed in other studies evaluating various formulations of a RSV recombinant F nanoparticle vaccine in pre-exposed participants [29,32].",
            "startOffset": 41562,
            "title": "Discussion"
        },
        {
            "endOffset": 33428,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Through Day 7 post-dose 2, these were reported by 33\u201354% (non-adjuvanted RSV F subunit groups), by 39\u201358% (RSV F subunit-Al groups), by 41\u201354% (RSV F subunit-MF59 groups) and by 46\u201350% (placebo groups) of participants (Table 2).",
            "startOffset": 33200,
            "title": "Safety"
        },
        {
            "endOffset": 28769,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Following a fixation step, RSV-infected cells were detected using a primary goat anti-RSV polyclonal antibody directed against viral antigens included in RSV-A and RSV-B, which was obtained in goats immunized with a viral lysate of human RSV isolates, and a secondary anti-goat antibody (IgG) conjugated with fluorescein isothiocyanate, allowing the visualization of plaques by immunofluorescence.",
            "startOffset": 28372,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 35402,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "During the entire follow-up, one NOCD was reported in a participant in the RSV F subunit-MF59 group of the 90 \u00b5g cohort (Basedow-Graves disease), which was not considered to be possibly related to vaccination.",
            "startOffset": 35193,
            "title": "Safety"
        },
        {
            "endOffset": 21581,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 21370,
                    "startOffset": 21363
                },
                "b0080": {
                    "endOffset": 21370,
                    "startOffset": 21363
                },
                "b0085": {
                    "endOffset": 21370,
                    "startOffset": 21363
                },
                "b0090": {
                    "endOffset": 21370,
                    "startOffset": 21363
                },
                "b0095": {
                    "endOffset": 21370,
                    "startOffset": 21363
                }
            },
            "secId": "s0005",
            "sentence": "As maternal antibodies partially protect infants from RSV disease and the accompanying bronchiolitis in their first months of life [15\u201319], immunization of pregnant women against RSV during the third trimester of gestation has the potential to passively protect young infants from the disease through placental or breast milk transfer of antibodies.",
            "startOffset": 21232,
            "title": "Introduction"
        },
        {
            "endOffset": 24289,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Women of childbearing potential had to practice contraceptive methods from at least two months prior to study entry through at least three weeks after the last study vaccination.",
            "startOffset": 24111,
            "title": "Study design and participants"
        },
        {
            "endOffset": 29242,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Binding antibody titers to RSV F, G (Ga and Gb), and N proteins were measured by a microsphere-based fluorescence multiplex enzyme-linked immunosorbent assay, using Luminex\u00ae technology.",
            "startOffset": 29057,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 42051,
            "parents": [],
            "secId": "s0065",
            "sentence": "Although no statistically significant differences across treatment groups were observed, immune responses tended to last longer for participants who received the RSV F subunit 135 \u00b5g dosage.",
            "startOffset": 41861,
            "title": "Discussion"
        },
        {
            "endOffset": 37615,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Among the groups who received the RSV F subunit vaccine (any formulation), total binding antibody GMTs to RSV F protein ranged from 9,641 to 13,541 at one month post-dose 1 (Day 29), and were slightly lower at one month post-dose 2, ranging from 8,064 to 13,483 at Day 57.",
            "startOffset": 37343,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 41561,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 41560,
                    "startOffset": 41556
                }
            },
            "secId": "s0065",
            "sentence": "Upon administration of the second vaccine dose, the injected F protein antigen is likely bound by circulating antibodies before it can be recognized and internalized by memory B cells to subsequently acquire the necessary T-cell help [31].",
            "startOffset": 41322,
            "title": "Discussion"
        },
        {
            "endOffset": 29056,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The assay cut-off was set at 8 ED60.",
            "startOffset": 29020,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 30134,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "This sample size was not driven by statistical assumptions for formal hypothesis testing; therefore, the analyses presented were purely descriptive and no inferential analysis was performed.",
            "startOffset": 29944,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 34538,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Among participants receiving the 45 \u00b5g dosage, one SAE was reported in the non-adjuvanted RSV F subunit group (acute pancreatitis), one in the RSV F subunit-Al group (cartilage injury) and one in the RSV F subunit-MF59 group (deep vein thrombosis).",
            "startOffset": 34290,
            "title": "Safety"
        },
        {
            "endOffset": 43159,
            "parents": [],
            "secId": "s0065",
            "sentence": "The ratios of the RSV F total binding antibody fold changes to the NAb fold changes were >3 in all groups from the RSV F subunit 90 and 135 \u00b5g cohorts at all post-vaccination timepoints, and were >2 in the RSV F subunit 45 \u00b5g cohort.",
            "startOffset": 42926,
            "title": "Discussion"
        },
        {
            "endOffset": 32403,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The mean age of the participants ranged from 27.6 to 32.9 years across all groups (Table 1).",
            "startOffset": 32311,
            "title": "Study population"
        },
        {
            "endOffset": 25031,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study protocol and informed consent/assent forms were reviewed and approved by the Independent Ethics Committee of the Ghent University Hospital.",
            "startOffset": 24882,
            "title": "Study design and participants"
        },
        {
            "endOffset": 26822,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The 3 dosages of the RSV F subunit vaccine evaluated in this study were lyophilized vaccines containing 45 \u00b5g, 90 \u00b5g or 135 \u03bcg of RSV F glycoprotein, each reconstituted either with sterile saline 0.9% NaCl (non-adjuvanted RSV F subunit groups), in sterile saline 0.9% NaCl and 1 mg aluminum hydroxide (RSV F subunit-Al groups) or in sterile saline 0.9% NaCl and the adjuvant MF59 containing 9.75 mg squalene and surfactants (RSV F subunit-MF59 groups).",
            "startOffset": 26370,
            "title": "Study vaccine"
        },
        {
            "endOffset": 42474,
            "parents": [],
            "refoffsets": {
                "b0140": {
                    "endOffset": 42473,
                    "startOffset": 42469
                }
            },
            "secId": "s0065",
            "sentence": "The lack of impact of the adjuvant on the persistence of NAb titers has previously been observed for aluminum-adjuvanted RSV prefusion F protein vaccine formulations [28].",
            "startOffset": 42303,
            "title": "Discussion"
        },
        {
            "endOffset": 20633,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 20632,
                    "startOffset": 20628
                }
            },
            "secId": "s0005",
            "sentence": "The neutralizing monoclonal antibody palivizumab is alternatively used for prophylaxis in infants at highest risk for severe infection, but is considered too expensive and impractical for universal use [10].",
            "startOffset": 20426,
            "title": "Introduction"
        },
        {
            "endOffset": 35703,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "All participants were seropositive for anti-RSV NAbs at baseline, with adjusted NAb GMTs ranging from 184 (95% CI: 127\u2013266) to 380 (95% CI: 272\u2013531) across all groups (Fig. 3).",
            "startOffset": 35527,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 37150,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In the participants who received any formulation of the RSV F subunit vaccine, at least 4-fold increases in anti-RSV NAb titers compared with baseline were observed in 25\u201358% of participants at Day 29, in 17\u201354% of participants at Day 57, and in 5\u201332% of participants at Day 181.",
            "startOffset": 36871,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 25534,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The primary objectives were to assess the safety of the RSV F subunit vaccine and to evaluate the serum NAb response to the RSV F subunit vaccine at 28 days after the second dose (Day 57).",
            "startOffset": 25346,
            "title": "Study objectives"
        },
        {
            "endOffset": 21975,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 21974,
                    "startOffset": 21967
                },
                "b0120": {
                    "endOffset": 21974,
                    "startOffset": 21967
                }
            },
            "secId": "s0005",
            "sentence": "Eleven proteins are coded by the RSV genome, among which the RSV fusion glycoprotein (RSV F), a surface protein that mediates the fusion between the virus envelope and the target respiratory epithelial cells and is essential to RSV pathogenesis [23,24].",
            "startOffset": 21722,
            "title": "Introduction"
        },
        {
            "endOffset": 24111,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "A Data Monitoring Committee reviewed safety data during scheduled periodic reviews: (1) after enrollment of the first 12 participants in each cohort; (2) seven days after the first dose, before proceeding with enrollment of the remaining participants in that cohort; and (3) after the enrollment of each cohort has been completed, before proceeding to the dosage escalation in the subsequent cohort.",
            "startOffset": 23712,
            "title": "Study design and participants"
        },
        {
            "endOffset": 38582,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Of note, data of participants showing 4-fold increases in G or N serotype due to natural infections were excluded from the per-protocol-set for immunogenicity (Fig. 2).",
            "startOffset": 38414,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 35163,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "No participants in the placebo groups reported SAEs.",
            "startOffset": 35111,
            "title": "Safety"
        },
        {
            "endOffset": 20322,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 20250,
                    "startOffset": 20243
                },
                "b0030": {
                    "endOffset": 20250,
                    "startOffset": 20243
                },
                "b0035": {
                    "endOffset": 20250,
                    "startOffset": 20243
                },
                "b0040": {
                    "endOffset": 20321,
                    "startOffset": 20318
                }
            },
            "secId": "s0005",
            "sentence": "Respiratory tract infections caused by RSV impact almost all children by the age of two years [3,6,7] and represent 22% of all episodes of acute LRTIs in young children [8].",
            "startOffset": 20149,
            "title": "Introduction"
        },
        {
            "endOffset": 35510,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The hematological and biochemical parameters were within normal ranges in all study groups (data not shown).",
            "startOffset": 35402,
            "title": "Safety"
        },
        {
            "endOffset": 26057,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The secondary objectives were to further evaluate the immune response to the RSV F subunit vaccine or placebo in terms of NAb titers and serum total binding antibody titers to the RSV F, G and N proteins at baseline (Day 1), 28 days post-dose 1 (Day 29), 28 days post-dose 2 (Day 57) and six months post-dose 1 (Day 181); and to compare the ratio of the serum total binding antibody geometric mean titers (GMTs) to the RSV F protein to the NAb GMTs in RSV F subunit vaccine or placebo recipients at Days 1, 29, 57, and 181.",
            "startOffset": 25534,
            "title": "Study objectives"
        },
        {
            "endOffset": 28050,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0130": {
                    "endOffset": 28049,
                    "startOffset": 28045
                }
            },
            "secId": "s0035",
            "sentence": "These consisted of the evaluation of serum anti-RSV NAb titers by a plaque reduction neutralization assay, as previously described [26].",
            "startOffset": 27914,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 39983,
            "parents": [],
            "secId": "s0065",
            "sentence": "Even if the highest levels of NAb GMTs were reached with the vaccine containing the highest dosage of recombinant RSV F glycoprotein, no considerable differences in antibody titers were detected between the various antigen levels (GMTs: 45 \u00b5g, 893\u2013983; 90 \u00b5g, 981\u20131,208; 135 \u00b5g, 1,123\u20131,602).",
            "startOffset": 39691,
            "title": "Discussion"
        },
        {
            "endOffset": 45770,
            "parents": [],
            "secId": "s0070",
            "sentence": "The immune responses were maintained above pre-vaccination levels for at least six months after the first dose.",
            "startOffset": 45659,
            "title": "Conclusions"
        },
        {
            "endOffset": 23324,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Participants were enrolled (1:1:1) in a stepwise dosage-escalation manner into three cohorts to receive either 45 \u03bcg, 90 \u03bcg, or 135 \u03bcg of the RSV F subunit vaccine (Fig. 1).",
            "startOffset": 23151,
            "title": "Study design and participants"
        },
        {
            "endOffset": 39331,
            "parents": [],
            "secId": "s0065",
            "sentence": "Rates of reported solicited and unsolicited events were similar across all dosages of the RSV F subunit vaccine and for both adjuvants.",
            "startOffset": 39196,
            "title": "Discussion"
        },
        {
            "endOffset": 42302,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 42301,
                    "startOffset": 42297
                }
            },
            "secId": "s0065",
            "sentence": "The observations likely results from the longer persistence of the antigen on follicular dendritic cells, allowing for a longer stimulation of B cells in the germinal centers, and the less pronounced inhibiting effect of pre-existing antibodies [31].",
            "startOffset": 42052,
            "title": "Discussion"
        },
        {
            "endOffset": 21232,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 21077,
                    "startOffset": 21073
                },
                "b0070": {
                    "endOffset": 21231,
                    "startOffset": 21227
                }
            },
            "secId": "s0005",
            "sentence": "The induction of neutralizing antibodies (NAbs) through vaccination may help to protect the population at-risk [12] since the severity of RSV disease is largely determined by the extent of viral replication among other environmental, social, host and viral factors [14].",
            "startOffset": 20962,
            "title": "Introduction"
        },
        {
            "endOffset": 32145,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Analysis of the GMRs of the RSV F total binding antibody titer fold changes to the NAb titer fold changes used an ANOVA model with dosage group as a fixed factor.",
            "startOffset": 31983,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 34089,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "None of these AEs were considered to be possibly related to vaccination.",
            "startOffset": 34017,
            "title": "Safety"
        },
        {
            "endOffset": 44317,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 44258,
                    "startOffset": 44254
                },
                "b0145": {
                    "endOffset": 44151,
                    "startOffset": 44147
                }
            },
            "secId": "s0065",
            "sentence": "The immune responses induced by the different formulations of the investigational RSV F subunit vaccine were similar to those induced by a recombinant F nanoparticle vaccine [29] and another adjuvanted investigational RSV vaccine based on protein F in its post-fusion conformation [13], which both failed to prevent RSV disease in older adults.",
            "startOffset": 43973,
            "title": "Discussion"
        },
        {
            "endOffset": 22145,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 22144,
                    "startOffset": 22140
                }
            },
            "secId": "s0005",
            "sentence": "An investigational RSV subunit vaccine (RSV F subunit vaccine) has been developed from an engineered recombinant RSV F glycoprotein in its post-fusion conformation [25].",
            "startOffset": 21976,
            "title": "Introduction"
        },
        {
            "endOffset": 26971,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The RSV F subunit vaccine (0.5 mL) or placebo (sterile saline 0.9% NaCl) was injected intramuscularly in the deltoid muscle of the non-dominant arm.",
            "startOffset": 26823,
            "title": "Study vaccine"
        },
        {
            "endOffset": 38271,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The results of a post-hoc analysis showed that the GMRs of the RSV F total binding antibody titer fold changes to the NAb titer fold changes ranged from 2.60 to 5.51 across all groups and timepoints in the RSV F subunit cohorts, while the GMRs in the placebo groups were close to 1 at all timepoints (Table 4).",
            "startOffset": 37961,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 43973,
            "parents": [],
            "secId": "s0065",
            "sentence": "No increase in total binding antibody titers to RSV proteins G and N was observed; however, data from seven participants demonstrating 4-fold increases in antibody titers to RSV proteins G and N due to natural infections were excluded from the per-protocol-set.",
            "startOffset": 43712,
            "title": "Discussion"
        },
        {
            "endOffset": 36302,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In the three cohorts, anti-RSV NAb GMTs were slightly lower at one month post-dose 2 (Day 57) compared to one month post-dose 1 (Day 29), with the highest level observed in the RSV F subunit-M59 group of the 135 \u00b5g cohort at Day 57 (NAb GMT: 1,316; 3.75-fold increase from baseline).",
            "startOffset": 36019,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 45227,
            "parents": [],
            "secId": "s0065",
            "sentence": "No formal conclusion could be drawn since this was an exploratory trial, which was not powered for hypotheses testing between dosage groups.",
            "startOffset": 45087,
            "title": "Discussion"
        },
        {
            "endOffset": 32762,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Until Day 7 post-dose 1, solicited local symptoms were reported by 50\u201358% (non-adjuvanted RSV F subunit groups), by 79\u201392% (RSV F subunit-Al groups), by 79\u201383% (RSV F subunit-MF59 groups) and by 8\u201321% (placebo groups) of participants.",
            "startOffset": 32528,
            "title": "Safety"
        },
        {
            "endOffset": 43711,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 43710,
                    "startOffset": 43706
                },
                "b0130": {
                    "endOffset": 43598,
                    "startOffset": 43594
                },
                "b0145": {
                    "endOffset": 43551,
                    "startOffset": 43547
                }
            },
            "secId": "s0065",
            "sentence": "These results show that the vaccine also induces non-neutralizing antibodies, which was also observed with a recombinant F nanoparticle vaccine [29], with the RSV prefusion F protein vaccine [26] and with another adjuvanted investigational RSV vaccine based on protein F in its post-fusion conformation [13].",
            "startOffset": 43403,
            "title": "Discussion"
        },
        {
            "endOffset": 38893,
            "parents": [],
            "secId": "s0065",
            "sentence": "This first-in-human phase I study showed that various dosages (45 \u00b5g, 90 \u00b5g and 135 \u00b5g of RSV F glycoprotein) and formulations (unadjuvanted or adjuvanted with aluminum or MF59) of the investigational RSV F subunit vaccine had a clinically acceptable safety profile and no safety signal was detected.",
            "startOffset": 38593,
            "title": "Discussion"
        },
        {
            "endOffset": 27387,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Symptom intensity was graded between 0 and 3, as absent, mild, moderate, and severe.",
            "startOffset": 27303,
            "title": "Safety assessment"
        },
        {
            "endOffset": 33199,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Post-dose 1, solicited systemic symptoms were reported by 54\u201358% (non-adjuvanted RSV F subunit groups), by 58% (RSV F subunit-Al groups), by 58\u201379% (RSV F subunit-MF59 groups) and by 50\u201371% (placebo groups) of participants (Table 2).",
            "startOffset": 32966,
            "title": "Safety"
        },
        {
            "endOffset": 25327,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Anonymized individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.",
            "startOffset": 25192,
            "title": "Study design and participants"
        },
        {
            "endOffset": 29019,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The serum neutralizing antibody titer was expressed as the estimated dilution 60 (ED60), which corresponds to the inverse of the interpolated serum dilution that yields a 60% reduction in the number of plaques as compared to the virus control wells.",
            "startOffset": 28770,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 23711,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The minimum interval between the two doses was 28 days.",
            "startOffset": 23656,
            "title": "Study design and participants"
        },
        {
            "endOffset": 31982,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Analyses of the ratio of the serum total binding antibody titers to the RSV F protein to the NAb titers used an ANCOVA model with dosage level and adjuvant as factors and the serum NAb titer at baseline as covariate.",
            "startOffset": 31766,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 45324,
            "parents": [],
            "secId": "s0065",
            "sentence": "A further limitation was the lack of correlates of protection for the assays used in this study.",
            "startOffset": 45228,
            "title": "Discussion"
        },
        {
            "endOffset": 27699,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Serious AEs (SAEs), unsolicited AEs leading to study withdrawal, new onsets of chronic disease (NOCDs; defined as an AE representing a new diagnosis of a chronic medical condition that was not present or suspected in a participant prior to study enrollment) were recorded from study start until study completion.",
            "startOffset": 27387,
            "title": "Safety assessment"
        },
        {
            "endOffset": 20148,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 20147,
                    "startOffset": 20144
                }
            },
            "secId": "s0005",
            "sentence": "In 2015, RSV caused an estimated 33.1 million acute lower respiratory tract infections (LRTI) among children younger than 5 years, resulting in 94,600 to 149,400 deaths [5].",
            "startOffset": 19975,
            "title": "Introduction"
        },
        {
            "endOffset": 30742,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The primary immunogenicity analyses were based on the per-protocol sets for immunogenicity at each timepoint (Fig. 2), which included all participants who received a study vaccination, provided immunogenicity data at the relevant timepoints, and were not excluded prior to unblinding or analysis.",
            "startOffset": 30446,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 42623,
            "parents": [],
            "secId": "s0065",
            "sentence": "This finding, together with our results, suggests that the saturation level may already be reached with the unadjuvanted formulation of the vaccine.",
            "startOffset": 42475,
            "title": "Discussion"
        },
        {
            "endOffset": 36758,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "At all timepoints, anti-RSV NAb GMTs were comparable between groups who received the RSV F subunit vaccine with different adjuvants and dosage levels.",
            "startOffset": 36608,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 37960,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Ratios of RSV F NAb GMTs over total binding antibody GMTs to the RSV F protein ranged from 2.00 to 3.95 at Day 1, from 9.21 to 12.0 at Day 29, from 8.95 to 13.0 at Day 57, and from 8.37 to 13.0 at Day 181 (Fig. 4).",
            "startOffset": 37746,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 19974,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 19825,
                    "startOffset": 19822
                },
                "b0010": {
                    "endOffset": 19973,
                    "startOffset": 19968
                },
                "b0015": {
                    "endOffset": 19973,
                    "startOffset": 19968
                },
                "b0020": {
                    "endOffset": 19973,
                    "startOffset": 19968
                },
                "b0025": {
                    "endOffset": 19973,
                    "startOffset": 19968
                }
            },
            "secId": "s0005",
            "sentence": "Although human respiratory syncytial virus (RSV) is a leading cause of respiratory distress and hospitalization in all age groups [1], infants younger than six months are at increased risk for severe RSV diseases, including bronchiolitis, pneumonia, rhinitis and otitis media [2\u20135].",
            "startOffset": 19692,
            "title": "Introduction"
        },
        {
            "endOffset": 41321,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 41320,
                    "startOffset": 41316
                }
            },
            "secId": "s0065",
            "sentence": "This observation could partially be explained by the high levels of pre-existing NAb titers as consequence of previous exposure to RSV during lifetime and the antibody levels achieved with the first vaccine dose [31].",
            "startOffset": 41104,
            "title": "Discussion"
        },
        {
            "endOffset": 29720,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "We verified assay specificity using samples from immunization with the RSV F vaccine that elicited antibody responses against RSV F protein only and samples from natural infection that elicited increases in antibody titers against RSV F, G and N proteins.",
            "startOffset": 29465,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 32465,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The proportion of women ranged from 58% to 92% in all groups.",
            "startOffset": 32404,
            "title": "Study population"
        },
        {
            "endOffset": 31426,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Proportions of participants with a \u22654-fold increase in serum anti-RSV NAb titers between baseline and Days 29, 57 and 181 were presented for each treatment group within each cohort, together with their two-sided 95% Clopper-Pearson CIs.",
            "startOffset": 31190,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 24684,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The exhaustive list of exclusion criteria is provided in Supplement 1.",
            "startOffset": 24614,
            "title": "Study design and participants"
        },
        {
            "endOffset": 34290,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Post-dose 2, 35\u201354% (non-adjuvanted RSV F subunit groups), 29\u201350% (RSV F subunit-Al groups), 27\u201370% (RSV F subunit-MF59 groups) and 42\u201354% (placebo groups) of participants reported any unsolicited AE.",
            "startOffset": 34090,
            "title": "Safety"
        },
        {
            "endOffset": 32195,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "All analyses were performed using SAS version 9.3.",
            "startOffset": 32145,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 45930,
            "parents": [],
            "secId": "s0070",
            "sentence": "A plain language summary contextualizing the results and potential clinical research relevance and impact is displayed in the Focus on Patient Section (Fig. 5).",
            "startOffset": 45770,
            "title": "Conclusions"
        },
        {
            "endOffset": 43402,
            "parents": [],
            "secId": "s0065",
            "sentence": "In the adjuvanted groups of the RSV F subunit 90 and 135 \u00b5g cohorts, there was a slight increase in the GMRs of the RSV F total binding antibody fold changes to the NAb fold changes between Day 29 and Day 57 followed by a decrease at Day 181.",
            "startOffset": 43160,
            "title": "Discussion"
        },
        {
            "endOffset": 27302,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Solicited local (injection site induration, swelling, erythema, and pain) and systemic (fever, chills, nausea, myalgia, arthralgia, headache, fatigue, diarrhea, cough, rhinorrhea, and wheezing) symptoms were recorded within seven days, and unsolicited adverse events (AEs) within 28 days after each vaccination.",
            "startOffset": 26991,
            "title": "Safety assessment"
        },
        {
            "endOffset": 41103,
            "parents": [],
            "secId": "s0065",
            "sentence": "No further increase of immune responses was observed after the second dose of the RSV F subunit vaccine, as similar or slightly lower levels of NAb titers were observed at 28 days after the second compared to the first dose for all formulations.",
            "startOffset": 40858,
            "title": "Discussion"
        },
        {
            "endOffset": 39596,
            "parents": [],
            "refoffsets": {
                "b0135": {
                    "endOffset": 39595,
                    "startOffset": 39591
                }
            },
            "secId": "s0065",
            "sentence": "The absence of impact of the adjuvants on the reactogenicity was an unexpected finding, especially for the MF59 adjuvant, which was previously associated with increased risk of solicited local or systemic adverse reactions compared to non-adjuvanted vaccines [27].",
            "startOffset": 39332,
            "title": "Discussion"
        },
        {
            "endOffset": 28371,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The serum-virus mixture was then transferred onto a monolayer of Vero cells and incubated for three days to allow infection by non-neutralized virus and formation of plaques.",
            "startOffset": 28197,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 42925,
            "parents": [],
            "secId": "s0065",
            "sentence": "Besides the increases in NAb titers, which are directed against a very specific part of RSV F protein, the RSV subunit vaccine also induced increases in serum total binding antibody titers to RSV F protein, which are directed against a wide variety of non-neutralizing epitopes of this complex protein.",
            "startOffset": 42623,
            "title": "Discussion"
        },
        {
            "endOffset": 44517,
            "parents": [],
            "refoffsets": {
                "b0165": {
                    "endOffset": 44516,
                    "startOffset": 44509
                },
                "b0170": {
                    "endOffset": 44516,
                    "startOffset": 44509
                }
            },
            "secId": "s0065",
            "sentence": "Recently, antibodies to the RSV F protein in its pre-fusion conformation were shown to have greater neutralizing activity than antibodies to the RSV F protein in its post-fusion conformation [33,34].",
            "startOffset": 44318,
            "title": "Discussion"
        },
        {
            "endOffset": 26354,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Since serum total binding antibody titers to the RSV F protein and NAb titers are measured by different assay systems and cannot be directly compared, an additional analysis was performed to evaluate the ratios of the RSV F total binding antibody titer fold changes to the NAb titer fold changes.",
            "startOffset": 26058,
            "title": "Study objectives"
        },
        {
            "endOffset": 36366,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Anti-RSV NAb GMTs decreased further between Day 57 and Day 181.",
            "startOffset": 36303,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 22595,
            "parents": [],
            "secId": "s0005",
            "sentence": "The purpose of this first-in-human phase I study was to evaluate the safety and immunogenicity of different dosages and formulations of the investigational RSV F subunit vaccine.",
            "startOffset": 22417,
            "title": "Introduction"
        },
        {
            "endOffset": 36018,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Anti-RSV NAb GMTs rose from Day 1 to Day 29 in all groups who received the RSV F subunit vaccine, with the highest levels reached in the RSV F subunit-Al group (NAb GMT: 1602; 4.58-fold increase from baseline and the RSV F subunit-MF59 group (NAb GMT: 1,551; 4.44-fold increase from baseline) of the 135 \u00b5g cohort.",
            "startOffset": 35704,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 37746,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Total binding antibody GMTs to RSV F protein decreased further between Day 57 and Day 181, ranging from 4,904 to 8,651 at Day 181.",
            "startOffset": 37616,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 25191,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study is registered at www.clinicaltrials.gov (NCT02298179) and a protocol summary is available at http://www.gsk-clinicalstudyregister.com (study 205219).",
            "startOffset": 25032,
            "title": "Study design and participants"
        },
        {
            "endOffset": 35110,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "No SAEs were considered as probably related to vaccination by the investigators.",
            "startOffset": 35030,
            "title": "Safety"
        },
        {
            "endOffset": 32966,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Post-dose 2, these were reported by 61\u201367% (non-adjuvanted RSV F subunit groups), by 46\u201354% (RSV F subunit-Al groups), by 57\u201364% (RSV F subunit-MF59 groups) and by 0\u201321% (placebo groups) of participants.",
            "startOffset": 32763,
            "title": "Safety"
        },
        {
            "endOffset": 44784,
            "parents": [],
            "refoffsets": {
                "b0170": {
                    "endOffset": 44783,
                    "startOffset": 44776
                },
                "b0175": {
                    "endOffset": 44783,
                    "startOffset": 44776
                },
                "b0180": {
                    "endOffset": 44783,
                    "startOffset": 44776
                }
            },
            "secId": "s0065",
            "sentence": "In particular, antibodies to the site \u00d8, which are not induced by the RSV F protein in its post-fusion conformation, are more important than those to the site II, which are induced by the RSV F protein in both its pre-fusion and its post-fusion conformation [34\u201336].",
            "startOffset": 44518,
            "title": "Discussion"
        },
        {
            "endOffset": 23655,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Within each cohort, participants were randomized (1:1:1:1) to receive two doses of the RSV F subunit vaccine without adjuvant (non-adjuvanted RSV F subunit groups), with 1 mg aluminum hydroxide (RSV F subunit-Al groups) or with 9.75 mg squalene and surfactants (MF59; RSV F subunit-MF59 groups), or saline placebo (placebo group).",
            "startOffset": 23325,
            "title": "Study design and participants"
        },
        {
            "endOffset": 20961,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 20687,
                    "startOffset": 20683
                },
                "b0060": {
                    "endOffset": 20960,
                    "startOffset": 20953
                },
                "b0065": {
                    "endOffset": 20960,
                    "startOffset": 20953
                }
            },
            "secId": "s0005",
            "sentence": "Despite a consensus on the need of a RSV vaccine [11], there is no licensed product available yet, mainly due to the early age of infection, the capacity of RSV to evade innate immunity, the failure of RSV-induced adaptive immunity to prevent re-infection and the lack of success with candidate vaccines in the elderly [12,13].",
            "startOffset": 20634,
            "title": "Introduction"
        },
        {
            "endOffset": 24881,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Written informed consent was obtained from each participant prior to enrollment.",
            "startOffset": 24801,
            "title": "Study design and participants"
        },
        {
            "endOffset": 38413,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "No changes in terms of total binding antibody GMTs to RSV Ga, Gb and N proteins were observed at any timepoint in all groups (data not shown).",
            "startOffset": 38271,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 40476,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 40475,
                    "startOffset": 40471
                },
                "b0140": {
                    "endOffset": 40285,
                    "startOffset": 40281
                },
                "b0145": {
                    "endOffset": 40363,
                    "startOffset": 40359
                }
            },
            "secId": "s0065",
            "sentence": "The immune responses induced by the RSV F subunit vaccine in our study were comparable to that previously observed with various formulations of another purified recombinant RSV F protein vaccine, which was engineered to preferentially maintain the prefusion conformation (RSV prefusion F protein) [28], with different formulations of a RSV recombinant F nanoparticle vaccine [29] and with another adjuvanted investigational RSV vaccine based on protein F in its post-fusion conformation [13].",
            "startOffset": 39984,
            "title": "Discussion"
        },
        {
            "endOffset": 41860,
            "parents": [],
            "secId": "s0065",
            "sentence": "A decline in immune responses was seen in all study groups during the 6-month follow-up following vaccination.",
            "startOffset": 41750,
            "title": "Discussion"
        }
    ],
    "docId": "S0264410X19304499",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "Geert.LerouxRoels@UGent.be",
                "first": "Geert",
                "initial": "G.",
                "last": "Leroux-Roels"
            },
            {
                "email": "Fien.DeBoever@uzgent.be",
                "first": "Fien",
                "initial": "F.",
                "last": "De Boever"
            },
            {
                "email": "Cathy.Maes@uzgent.be",
                "first": "Cathy",
                "initial": "C.",
                "last": "Maes"
            },
            {
                "email": null,
                "first": "Thi Lien Anh",
                "initial": "T.L.A.",
                "last": "Nguyen"
            },
            {
                "email": null,
                "first": "Sherryl",
                "initial": "S.",
                "last": "Baker"
            },
            {
                "email": "antonio.y.gonzalez@gsk.com",
                "first": "Antonio",
                "initial": "A.",
                "last": "Gonzalez Lopez"
            }
        ],
        "doi": "10.1016/j.vaccine.2019.04.011",
        "firstpage": "2694",
        "issn": "0264410X",
        "keywords": [
            "Adjuvant",
            "Glycoprotein",
            "Immunogenicity",
            "Respiratory syncytial virus",
            "Safety",
            "Subunit vaccine"
        ],
        "lastpage": "2703",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study"
    }
}